JP2023515974A5 - - Google Patents
Info
- Publication number
- JP2023515974A5 JP2023515974A5 JP2022551593A JP2022551593A JP2023515974A5 JP 2023515974 A5 JP2023515974 A5 JP 2023515974A5 JP 2022551593 A JP2022551593 A JP 2022551593A JP 2022551593 A JP2022551593 A JP 2022551593A JP 2023515974 A5 JP2023515974 A5 JP 2023515974A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- modified
- nucleic acid
- modified oligonucleotide
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983555P | 2020-02-28 | 2020-02-28 | |
| US62/983,555 | 2020-02-28 | ||
| US202063085111P | 2020-09-29 | 2020-09-29 | |
| US63/085,111 | 2020-09-29 | ||
| PCT/US2021/019960 WO2021174036A1 (en) | 2020-02-28 | 2021-02-26 | Compounds and methods for modulating scn1a expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515974A JP2023515974A (ja) | 2023-04-17 |
| JP2023515974A5 true JP2023515974A5 (enExample) | 2024-03-05 |
Family
ID=77491960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551593A Pending JP2023515974A (ja) | 2020-02-28 | 2021-02-26 | Ｓｃｎ１ａ発現を調節するための化合物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230043648A1 (enExample) |
| EP (1) | EP4110919A4 (enExample) |
| JP (1) | JP2023515974A (enExample) |
| TW (1) | TW202140788A (enExample) |
| UY (1) | UY39104A (enExample) |
| WO (1) | WO2021174036A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019239971B2 (en) * | 2018-03-21 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof |
| JP2024534157A (ja) * | 2021-08-27 | 2024-09-18 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｓｃｎ１ａ発現を調節するための化合物及び方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102213609B1 (ko) * | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| EP3484524B1 (en) * | 2016-07-15 | 2022-11-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
| KR102318434B1 (ko) * | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| US10758629B2 (en) * | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| BR112021003224A2 (pt) * | 2018-08-20 | 2021-07-20 | Rogcon, Inc. | oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a |
| BR112022010882A2 (pt) * | 2019-12-06 | 2022-10-04 | Stoke Therapeutics Inc | Oligômeros antissenso para tratamento de condições e doenças |
-
2021
- 2021-02-26 EP EP21760424.8A patent/EP4110919A4/en active Pending
- 2021-02-26 JP JP2022551593A patent/JP2023515974A/ja active Pending
- 2021-02-26 US US17/802,324 patent/US20230043648A1/en active Pending
- 2021-02-26 TW TW110107122A patent/TW202140788A/zh unknown
- 2021-02-26 WO PCT/US2021/019960 patent/WO2021174036A1/en not_active Ceased
- 2021-03-01 UY UY0001039104A patent/UY39104A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022103192A5 (enExample) | ||
| Koop et al. | A molecular view of primate phylogeny and important systematic and evolutionary questions. | |
| JP2023515974A5 (enExample) | ||
| JP2023536994A5 (enExample) | ||
| US6066447A (en) | Modified oligonucleotides | |
| JP2021530204A5 (enExample) | ||
| JPH07300493A (ja) | ２′−エーテル基を有する、ヌクレオシド及びオリゴヌクレオチド | |
| JP3831407B2 (ja) | メチルホスホン酸エステル、その製造方法およびその使用 | |
| JP2021512629A5 (enExample) | ||
| JP2022527105A5 (enExample) | ||
| JP2022518929A5 (enExample) | ||
| JP2020193199A5 (enExample) | ||
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| JP2024539629A5 (enExample) | ||
| JP2016522683A5 (enExample) | ||
| JP2013526860A5 (enExample) | ||
| AU2018297262A1 (en) | RNAi agents for inhibiting expression of alpha-ENaC and methods of use | |
| JP2024534157A5 (enExample) | ||
| JP2024541771A5 (enExample) | ||
| JP2024504377A5 (enExample) | ||
| JP2022515744A5 (enExample) | ||
| JP2024545602A5 (enExample) | ||
| JP2024536146A5 (enExample) | ||
| JP2024511473A5 (enExample) | ||
| JP2024523363A5 (enExample) |